In this touchENDOCRINOLOGY interview, Prof. Jennifer Clements (University of South Carolina, College of Pharmacy, Columbia, SC, USA) joins us to discuss a study investigating the efficacy and safety of once-daily vs twice-daily insulin glargine in non-critically ill patients.
The abstract entitled: ‘A Retrospective Analysis of Once-daily versus Twice-daily Dosing of Insulin Glargine in Non-critically Ill Patients’ was presented at the Association of Diabetes Care & Education Specialists (ADCES) Annual Conference, 12-15 Aug, 2022.
Questions:
- Could you tell us a little about the debate regarding the efficacy and safety of once-daily vs twice-daily insulin glargine in non-critically ill patients?
- What were the aims, design and inclusion criteria of your study?
- What were the findings of your study in terms of primary and secondary outcomes?
- What exploratory findings warrant further investigation?
- What future studies are needed?
Disclosures: Speaker’s bureau participant with Novo Nordisk on semaglutide.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of ADCES 2022
Click here for more related content.
